Network pharmacology analysis indicated that quercetin, luteolin, and baicalein may be important anticancer components in HD-SB, potentially acting on targets such as EGFR, MAPK1, VEGFA, and PIK3CG to inhibit ovarian cancer growth and migration via focal adhesion pathways [110]. Here, PIK3CG is linked to ovarian carcinoma.